Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.49 |
| ▸ | STK17B | O94768 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 13/20 | 0.44 |
| ▸ | LATS1 | O95835 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19665707 | 0.86 | PIN1 (0.51) | STK17ASTK17BPIN1MAPTL3MBTL1 | |
| SCHEMBL12968578 | 0.85 | STK17A (0.62) | STK17ASTK17BPIN1LATS1MAPT | |
| SCHEMBL29802454 | 0.84 | LATS1 (0.42) | STK17ALATS1MAPTL3MBTL1 | |
| SCHEMBL29802555 | 0.84 | STK17A (0.72) | STK17ASTK17BPIN1L3MBTL1 | |
| SCHEMBL29802473 | 0.83 | STK17B (0.46) | STK17ASTK17BPIN1MAPTL3MBTL1 | |
| SCHEMBL28644736 | 0.83 | STK17B (0.46) | STK17ASTK17BPIN1MAPTL3MBTL1 | |
| SCHEMBL28639498 | 0.82 | PIN1 (0.44) | STK17ASTK17BPIN1MAPTL3MBTL1 | |
| SCHEMBL4138613 | 0.81 | PIN1 (0.53) | STK17APIN1MAPTL3MBTL1 | |
| SCHEMBL29802583 | 0.81 | STK17A (0.49) | STK17ASTK17BPIN1MAPTL3MBTL1 | |
| SCHEMBL5095919 | 0.80 | PRKCQ (0.49) | STK17ASTK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464287-B1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11344554-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344554-B2 | Animal and human anti-malarial agents | HPRT1, UMPS, PNP | STK17A 3295/4885STK17B 3629/4885PIN1 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.